Newsletter Subscription


Wednesday, Oct 22, 2014


Implant Sciences' QS-B220 Benchtop Explosives and Narcotics Trace Detector Completes Certification Readiness Testing

  • Moves to Final TSA/TSL Independent Testing

Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that its QS-B220 Explosives and Narcotics Trace Detector has successfully completed the certification readiness testing with the Transportation Security Laboratory ("TSL"), the testing body of the Transportation Security Administration ("TSA"). The B220 is now undergoing the final independent validation testing for TSA qualification for air cargo screening.

"We are pleased to have been informed last week that our B220 system has successfully completed the certification readiness and verification testing and has now been accepted into final validation testing with the TSL. This is a major milestone for the Company. Entering into this final phase of approval gives us great confidence that our desktop B220 explosives trace detection system will be well positioned for adoption in the U.S. and global markets," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "While the next few weeks will be a quiet period during the final stage of testing, we remain confident in our system's performance and are hopeful that we will have good news to report to our shareholders by the end of our fiscal first quarter (ended September 30, 2012). This will put us in good position to capitalize on the December 3, 2012 date for the air cargo industry to comply with the mandates of air cargo screening regulations."


Related Research on ASDReports.com:
Global Military Satellite Market 2014-2024

Source : Implant Sciences Corp.

Published on ASDNews: Aug 22, 2012

 

Mine Countermeasures 2014 Conference

Nov 17 - 19, 2014 - London, United Kingdom

Register More info


© 2004-2014 • ASDNews • be the first to know • contact usterms & conditionsprivacy policyadvertisingfaqs